EcoDrugPlus

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSPNAG00000006286
Gene Symbol: MTOR
3 Cross references
217 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSPNAG00000004302
Gene Symbol: MC1R
1 Cross references
159 Possible Orthologues:

Melanocortin 3 Receptor

Ensembl ID : ENSPNAG00000018683
Gene Symbol: MC3R
1 Cross references
138 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSPNAG00000001943
Gene Symbol: MC4R
2 Cross references
82 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSPNAG00000022550
Gene Symbol: MC4R
1 Cross references
30 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSPNAG00000003779
Gene Symbol: MTNR1A
3 Cross references
136 Possible Orthologues:

Melatonin Receptor 1a A

Ensembl ID : ENSPNAG00000013576
Gene Symbol: MTNR1AA
1 Cross references
184 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSPNAG00000005244
Gene Symbol: MME
4 Cross references
234 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSPNAG00000016434
Gene Symbol: LOC108435310
3 Cross references
206 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSPNAG00000022025
Gene Symbol: LOC108444204
3 Cross references
215 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSPNAG00000026767
Gene Symbol: LOC108411478
3 Cross references
218 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSPNAG00000017514
Gene Symbol: LOC108423821
3 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).